Dr. Ian Kelleher (University of Edinburgh, Scotland) joins AJP Audio to discuss an emulated target trial looking at the prophylactic qualities of doxycycline, an antibiotic, in an adolescent population at risk to develop schizophrenia spectrum disorder. Afterwards, AJP Editor-in-Chief Dr. Ned Kalin joins the podcast to put the rest of the issue into context.

• 00:53 Doxycycline and the risk of developing schizophrenia
• 04:03 Emulated target trials versus randomized control trials
• 06:43 Methods of action
• 09:24 Dosage and exposure levels for doxycycline
• 10:15 Immediate clinical applications
• 10:56 Limitations of the study
• 11:33 Future research
• 12:43 Kalin interview
• 13:00 Lång et al.
• 19:43 Zhao et al.
• 25:20 Metrik et al.

Transcript

Be sure to let your colleagues know about the podcast, and please rate and review it on Apple Podcasts, Google Podcasts, Spotify, or wherever you listen to it.

Subscribe to the podcast here.

Listen to other podcasts produced by the American Psychiatric Association.

Browse articles online.

How authors may submit their work.

Follow the journals of APA Publishing on Twitter.

E-mail us at ajp@psych.org

This special episode of AJP Audio brings together the editors of the American Journal Psychiatry and the AJP Residents' Journal to discuss important and impactful articles published in 2025.

• 00:39 Ned H. Kalin, M.D., discusses "Transcriptomic Analysis of the Human Habenula in Schizophrenia" by Ege A. Yalcinbas, Ph.D., et al.
• 06:23 Elisabeth Binder, M.D., Ph.D., discusses "Copy Number Variant Architecture of Child Psychopathology and Cognitive Development in the ABCD Study" by Zhiqiang Sha, Ph.D., et al.
• 11:17 Kathleen T. Brady, M.D., Ph.D., discusses "High-Potency Cannabis Use and Health: A Systematic Review of Observational and Experimental Studies" by Stephanie Lake, Ph.D., et al.
• 15:35 David A. Lewis, M.D., discusses "20 Years of Aberrant Salience in Psychosis: What Have We Learned?" by Philip R. Corlett, Ph.D., and Kurt M. Fraser, Ph.D.
• 17:27 William M. McDonald, M.D., discusses "Psychedelics for the Treatment of Psychiatric Disorders: Interpreting and Translating Available Evidence and Guidance for Future Research" by Roger S. McIntyre, M.D., F.R.C.P.C., et al.
• 24:04 Daniel S. Pine, M.D., discusses "Cognitive Behavioral Therapy and Lisdexamfetamine, Alone and Combined, for Binge-Eating Disorder With Obesity: A Randomized Controlled Trial" by Carlos M. Grilo, Ph.D., et al.
• 26:06 Carolyn Rodriguez, M.D., Ph.D., discusses "Randomized Controlled Trial of the Effects of High-Dose Ondansetron on Clinical Symptoms and Brain Connectivity in Obsessive-Compulsive and Tic Disorders" by Emily R. Stern, Ph.D., et al.
• 30:26 Sean T. Lynch, M.D., discusses "From Medical Practice to Mass Incarceration: A Historical Analysis of Racial and Ethnic Targeting in U.S. Drug Policy" by Rathisha Pathmathasan, D.O., et al.

Transcript

Be sure to let your colleagues know about the podcast, and please rate and review it on Apple Podcasts, Google Podcasts, Spotify, or wherever you listen to it.

Subscribe to the podcast here.

Listen to other podcasts produced by the American Psychiatric Association.

Browse articles online.

How authors may submit their work.

Follow the journals of APA Publishing on Twitter.

E-mail us at ajp@psych.org

Dr. Julia Linke (University of Mainz, Germany) joins AJP Audio to discuss the use of neural efficiency, a measure of brain activity, as a potential biomarker in the treatment of children with anxiety disorder. Afterwards, AJP Editor-in-Chief Dr. Ned Kalin joins the podcast to put the rest of the issue into context.

• 00:31 Linke interview
• 02:15 State or a trait?
• 04:15 Neural efficiency and CBT
• 05:22 Potential as a biomarker
• 07:08 Patient-rated and parent-rated measures of anxiety
• 08:16 Immediate clinical implications
• 09:50 Limitations
• 10:43 Future directions of research
• 11:44 Kalin interview
• 11:50 Linke et al.
• 15:16 Mallard et al.
• 18:11 Naples et al.
• 21:44 Mac Giollabhui et al.

Transcript

Be sure to let your colleagues know about the podcast, and please rate and review it on Apple Podcasts, Google Podcasts, Spotify, or wherever you listen to it.

Subscribe to the podcast here.

Listen to other podcasts produced by the American Psychiatric Association.

Browse articles online.

How authors may submit their work.

Follow the journals of APA Publishing on Twitter.

E-mail us at ajp@psych.org

Dr. Suresh Durgam (Intra-Cellular Therapies, a Johnson & Johnson Company, Bedminster, NJ) joins AJP Audio to discuss a phase 3 randomized controlled trial looking at the use of the antipsychotic medication lumateperone as adjunctive to antidepressant therapy in the treatment of patients with major depressive disorder. Afterwards, AJP Editor-in-Chief Dr. Ned Kalin discusses the rest of the December issue of the Journal.

• 00:48 Durgam interview
• 03:09 Mechanism of action
• 04:44 Patient-reported outcomes
• 06:31 Immediate clinical implications
• 07:32 Limitations
• 08:08 Further research
• 09:25 Kalin interview
• 09:38 Durgam et al.
• 13:09 Lin et al.
• 17:22 Brodsky et al.

Transcript

Be sure to let your colleagues know about the podcast, and please rate and review it on Apple Podcasts, Google Podcasts, Spotify, or wherever you listen to it.

Subscribe to the podcast here.

Listen to other podcasts produced by the American Psychiatric Association.

Browse articles online.

How authors may submit their work.

Follow the journals of APA Publishing on Twitter.

E-mail us at ajp@psych.org

Dr. Lara Coughlin (University of Michigan, Ann Arbor) joins AJP Audio to discuss a study looking the impact of contingency management on all cause mortality in patients with stimulant use disorder. Afterwards, AJP Editor-in-Chief Dr. Ned Kalin discusses the rest of the November issue of the Journal.

• 01:09 Coughlin interview
• 02:05 Stimulant use disorder and contingency management
• 04:37 Mortality
• 05:12 Contingency management and "moral hazard"
• 08:30 Clinical uptake of contingency management
• 09:28 Broader applicability to psychiatric conditions
• 10:31 Limitations
• 11:39 Further research
• 12:32 Kalin interview
• 12:49 Coughlin et al.
• 16:41 Yalcinbas et al.
• 22:22 Na et al.

Transcript

Be sure to let your colleagues know about the podcast, and please rate and review it on Apple Podcasts, Google Podcasts, Spotify, or wherever you listen to it.

Subscribe to the podcast here.

Listen to other podcasts produced by the American Psychiatric Association.

Browse articles online.

How authors may submit their work.

Follow the journals of APA Publishing on Twitter.

E-mail us at ajp@psych.org

Dr. Shau-Ming Wei (National Institute of Mental Health, Bethesda, MD) joins AJP Audio to discuss a replication study looking at impact of hormone addback to a hormone suppression regimen for the treatment of premenstrual dysphoric disorder. Afterwards, AJP Editor-in-Chief Dr. Ned Kalin discusses the rest of the October issue of the Journal.

• 00:34 Wei interview
• 02:59 PMDD
• 04:22 Up and downsides of hormone suppression
• 05:52 Hormone addback
• 07:15 Limitations of the current study
• 08:38 Further research
• 10:42 Kalin interview
• 10:58 Wei et al.
• 15:25 Sanacora et al.
• 20:07 Whittle et al.
• 23:06 Cooper et al.

Transcript

Be sure to let your colleagues know about the podcast, and please rate and review it on Apple Podcasts, Google Podcasts, Spotify, or wherever you listen to it.

Subscribe to the podcast here.

Listen to other podcasts produced by the American Psychiatric Association.

Browse articles online.

How authors may submit their work.

Follow the journals of APA Publishing on Twitter.

E-mail us at ajp@psych.org

Dr. Deidre Anglin (City College, CUNY, New York) joins AJP Audio to discuss the disparate impact of schizophrenia spectrum disorder diagnosis on racial and ethnic minorities in the United States based on localized neighborhood data. Afterwards, AJP Editor-in-Chief Dr. Ned Kalin discusses the rest of the September issue of the Journal.

• 00:31 Anglin interview
• 04:40 Zip code sizes
• 05:18 The long legacy of redlining
• 07:17 Socially vulnerable neighborhoods
• 09:43 Structural racism, clinicians, and working with individuals
• 13:45 Limitations
• 15:56 Further research
• 18:08 Kalin interview
• 18:13 Anglin et al.
• 25:19 Vano et al.
• 29:40 Moussa-Tooks et al.
• 33:34 Zhang et al.

Transcript

Be sure to let your colleagues know about the podcast, and please rate and review it on Apple Podcasts, Google Podcasts, Spotify, or wherever you listen to it.

Subscribe to the podcast here.

Listen to other podcasts produced by the American Psychiatric Association.

Browse articles online.

How authors may submit their work.

Follow the journals of APA Publishing on Twitter.

E-mail us at ajp@psych.org

Dr. Vinod Rao (Massachusetts General Hospital, Boston) join AJP Audio to discuss predicting the relative risk of patients with an ADHD diagnosis developing a later stimulant or substance use disorder based on the method of prescription, in person or via telehealth. Afterwards, AJP Editor-in-Chief Dr. Ned Kalin discusses the rest of the August issue of the Journal.

• 00:07 Rao interview
• 01:53 Stimulant use disorder versus substance use disorder
• 02:59 Cohort size and incidence of SUDs
• 04:28 Length of clinician engagement in non-profit versus for profit hospital systems
• 05:18 Patient cohort
• 06:20 Potential difference in mechanism between prescribing practices
• 07:35 Continued use of telehealth
• 08:43 Limitations
• 10:03 Further research
• 11:17 Kalin interview
• 11:24 Rao et al.
• 15:41 Mahjani et al.
• 19:59 Zhang et al.
• 25:11 Sha et al.
• 29:33 Gao and Olfson

Transcript

Be sure to let your colleagues know about the podcast, and please rate and review it on Apple Podcasts, Google Podcasts, Spotify, or wherever you listen to it.

Subscribe to the podcast here.

Listen to other podcasts produced by the American Psychiatric Association.

Browse articles online.

How authors may submit their work.

Follow the journals of APA Publishing on Twitter.

E-mail us at ajp@psych.org